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Abstract
Background: Osteoporosis is a major health problem worldwide, and is included in the WHO list of the top 10
major diseases. However, it is often undiagnosed until the first fracture occurs, due to inadequate patient
education and lack of insurance coverage for screening tests. Anamnestic risk factors like positive family anamnesis
or early menopause are assumed to correlate with reduced BMD.
Methods: In our study of 78 patients with metaphyseal long bone fractures, we searched for a correlation
between anamnestic risk factors, bone specific laboratory values, and the bone morphogenic density (BMD). Each
indicator was examined as a possible diagnostic instrument for osteoporosis. The secondary aim of this study was
to demonstrate the high prevalence of osteoporosis in patients with metaphyseal fractures.
Results: 76.9% of our fracture patients had decreased bone density and 43.6% showed manifest osteoporosis in DXA
(densitometry) measurements. Our questionnaire, identifying anamnestic risk factors, correlated highly significantly
(p = 0.01) with reduced BMD, whereas seven bone-specific laboratory values (p = 0.046) correlated significantly.
Conclusions: Anamnestic risk factors correlate with pathological BMD. The medical questionnaire used in this
study would therefore function as a cost-effective primary diagnostic instrument for identification of osteoporosis
patients.
Background
The WHO included osteoporosis in the list of the ten
major worldwide diseases [1]. Approximately 200 million
patients worldwide, 44 million in the US and about 7.6
million in Germany, suffer from osteoporosis [2-4]. The
high prevalence of osteoporosis in current populations
becomes more stressing to health care systems as osteo-
porosis rates increase with age, and as populations adopt
unhealthy lifestyles with reduced physical activity and
unbalanced diets [5]. In the western industrial nations
there is an immense imbalance between inadequately
treated osteoporosis and the continually increasing life
expectancies [6]. In Germany, costs incurred due to
osteoporosis result from osteoporosis associated
fractures, especially fractures of proximal femur, and
include acute care, rehabilitation, and extended nursing
care. All in all, the expenditure amounts to 5 billion
euros annually [6,7]. A proximal femur fracture is often
the first indication of manifest osteoporosis. Preventional
diagnostics such as DXA-measuring or laboratory exami-
nation, amounting to approximately 15 million euros per
year, are not currently covered by health insurance.
There are various risk factors, which are assumed to
highly correlate with osteoporosis. These are anamnestic
details of the patient’s medical history as for example:
positive family anamnesis, early menopause, nicotine
abuse, age > 70 years. They are included as osteoporosis-
specific risk factors in the recommendations of the
German Society of Osteology (DVO, Dachverband Osteo-
logie e.V.). The aim of this study is to demonstrate the
high prevalence of osteoporosis in patients with metaphy-
seal fractures, and, secondly, to show the competence of
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anamnestic risk factors and bone specific laboratory values
in osteoporosis identification.
Methods
Between January 2008 and May 2010, 78 patients aged 40
to 80 years who presented to our hospital with a meta-
physeal fracture of the distal radius, proximal humerus
and proximal femur with an obligatory indication for sur-
gical stabilization were included in this study. Exclusion
criteria were: polytrauma, significant soft tissue injury,
extensive open fractures, > 24 h mechanical ventilation
after surgery, dialysis, collagenosis, chronic inflammatory
bowel disease, haematological disorders and malignan-
cies, and long-term therapy with immunosuppressants.
X-rays of the fracture region and the lumbar spine in
anterior-posterior and lateral views were performed of all
patients. Lumbar spine radiographs were used to exclude
morphological changes of the vertebrae leading to inaccu-
rate values in DXA bone density measurement. BMD was
examined at the lumbar spine, total hip and hip subregions
using dual energy X-ray absorptiometry DXA (Lunar
iDPX, GE Medical Systems Germany, Solingen, Germany)
based on Encore TM Version II.X software.
Using normative data for young Caucasian adults, BMD
was categorized as normal, low, or osteoporotic, as defined
by the World Health Organization [8]. Participants with a
T-score ≤ -2.5 SD were categorized as having osteoporosis.
To collect the anamnestic risk factors of patients, we
established a standardized questionnaire according to the
recommendations of the German Society of Osteology
(DVO, Dachverband Osteologie e.V.). The questionnaire
included clinical risk factors (19 for men, 21 for women)
as shown in table 1 [9]. The questionnaire was filled out
with one member of the study group present, to provide
assistance if needed.
Laboratory analysis was performed the morning after
injury in a fasting state. Eleven bone specific parameters
reflecting bone metabolism were examined: intact PTH
[10], 25-hydroxy vitamin D3 (25-OH-D3) [11], beta-
crosslaps (ß-CTX), pyridinoline in urine, desoxypyridi-
noline in urine (DPD) [10,12], procollagen type 1 N
propeptide (PINP) [10], creatinine in urine [13], estra-
diol [10], homocysteine, vitamin B12 and folate [14,15].
Every pathologic aberration from the standard value
was assessed with one point.
Statistics were performed using SPSS 11.0.0 (IBM
Germany, Munich, Germany) and Microsoft Excel 2003/
2007 software, Microsoft Corp. Washington, USA. Using
Spearman’s rank correlation coefficient, the single ana-
mnestic risk factors and laboratory parameters were corre-
lated with the reduced BMD values. P ≤ 0.05 was
considered to be significant and p ≤ 0.01 highly significant.
In addition we performed a multivariable analysis in order
to adjust for potential confounders. With the method of
“ordinal logistic regression” we examined age, sex and BMI
as possible confounders with the variables BMD, risk fac-
tors and laboratory values.
The study is approved by the local Ethical Committee
of Heidelberg with the approval number 1572002. All
patients gave their informed consent prior to their
inclusion in the study.
Results
A total of 78 patients who suffered a metaphyseal frac-
ture of the distal radius, proximal humerus or proximal
femur between January 2008 and May 2010 were
included in this study. The average patient age was 62.2
years with a range from 41.9 to 77.6 years. The 12 male
patients had an average age of 65.4 years, the 66 female
patients of 61.6 years. 41 patients had a distal radius
fracture, 23 patients a proximal humerus fracture and
14 patients suffered a proximal femur fracture.
In DXA-measuring 76.9% of patients showed a patholo-
gic bone density. 34 (43.6%) patients had a decrease in
bone density in terms of osteoporosis, 26 (33.3) patients
had osteopenic BMD. 18 (23.1%) of patients had physiolo-
gical findings (Figure 1). Among the male patients, 58.3%
showed manifest osteoporosis and 16.7% osteopenia.
Table 1 Medical questionnaire of anamnestic risk factors
for reduced BMD
men women total
Reduction of body height > 4 cm 3 9 12
Alcohole abuse 2 4 6
Age > 70 2 14 16
Anorexia nervosa 0 0 0
Anticonvulsive therapy 1 0 1
Already suffered osteoporotic fractures 2 9 11
BMI < 20 kg/m2 0 0 0
Chronical renal or hepatic disease 0 2 2
Family history 3 19 22
Early menopause (< 45. Lj.) - 13 13
Late menarche (> 15. Lj.) - 2 2
Highdose heparintherapy 0 1 1
Hormon replacement therapy 0 6 6
Hyperparathyroidism 0 0 0
Hyperthyroidism 0 4 4
(N)IDDM 1 3 4
Immobilisation, Inactivity 1 1 2
Malabsorption-syndrome 0 0 0
Multiple Sclerosis 0 1 1
Nikotine abuse 3 12 15
Rheumatoid Arthritis 0 4 4
The right columns show the frequence of aberrations of the single risk factors
in our study.
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Female patients showed in 40.9% manifest osteoporosis
and in 36.4% an osteopenia.
The frequency of the single anamnestic risk factors can
be seen in table 1. The leading risk factors are: positive
family history, age > 70 years, nicotine abuse, early meno-
pause, reduction of body height > 4 cm and previous
osteoporotic fractures. There was no incident of 4 risk
factors (anorexia nervosa, BMI < 20 kg/m2, hyperparathyr-
eoidism, malabsorption syndrome) in our collective.
Questionnaire risk factors correlated with reduced
bone density values. Spearman’s rank correlation allowed
separate consideration of the individual risk factors
reduced bone density. The 10 anamnestic risk factors:
reduce of body height > 4 cm, alcohol abuse, age > 70
years, anticonvulsant therapy, previous osteoporotic frac-
tures, early menopause (< 45years), hyperthyroidism,
immobilization, multiple sclerosis and nicotine abuse
showed a highly significant correlation (p = 0.01) with
low bone density (Figure 2).
Table 2 shows the frequency of pathological laboratory
values in our collective. Laboratory values of 67 patients
were evaluated; 11 patients declined blood sample collec-
tion. The main pathologic laboratory values are: homocys-
teine (51 patients), 25-OH-D3 (42 patients), and
desoxypyridinoline (31 Patients). The fewest aberrations
were seen in ß-CTX (13 patients), estradiol (7 patients)
and vitamin B12 (6 Patients) measurings.
For statistical analyses, Spearman’s rank was used to
correlate abnormal laboratory values with a decrease in
bone density. The highest correlation (p = 0.046) was
noted in parathyroid hormone, 25-OH-D3, procollagen
type 1 N propeptide, desoxypyridinoline, creatinine,
homocysteine and vitamin B12 (Figure 3).
The multivariable analysis showed no significant
effects with the variables; thus the age, sex and BMI of
patient do not have a confounding effect.
Discussion
In this study, nearly 80% of patients who suffered a
metaphyseal fracture showed pathologically reduced
bone mineral density, and nearly 50% of the patients





Figure 1 Results of DXA-measuring. Percentaged amount of healthy, osteopenic and osteoporotic values in women and men.
 
 
Number of anamnestic risk factors 
Lowest T-values in DXA-measuring
Figure 2 Diagram presenting the correlation between the
lowest T-values of DXA-measuring with increasing number of
anamnestic risk factors. The correlation of the most important risk
factors and a reduced BMD is highly significant (p = 0.01,
Spearman’s rank correlation).
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patients were postmenopausal women. Our results coin-
cide with current research; Vogel et al. [16] found osteo-
porosis in 72% of acute limb fracture patients (only 4%
showed normal bone density). Another Dutch study [17]
evaluated fractures resulting from low energy trauma
and found manifest osteoporosis in 67% of patients.
(Hegemann et al defined the T-Score as < -2.0 for
osteoporosis, compared to < -2.5 in our study).
Having identified one of the major problems in treat-
ment of osteoporosis: post fracture diagnosis; we have
identified the major cause of the progression of this dis-
ease: the therapeutic window in which to minimize frac-
ture risk is overlooked. Due to the exceptionally high
morbidity and mortality after osteoporotic fractures, pre-
vention is essential. However, as mentioned, the costs for
preventional screenings such as DXA-measurement or
laboratory examination (amounting to approximately
15 million euros per year) are not currently covered by
German health insurance companies [6]. Furthermore,
bone loss progresses silently, and without patient educa-
tion and preventional screenings, few patients would
recognize the risk [18,19].
A safe, simple and cost effective instrument for osteo-
porosis diagnosis is essential. The results of this study
show that a simple medical questionnaire containing 10
anamnestic questions is a reliable test to quickly and
efficiently screen large numbers of patients for reduced
BMD. With early detection of bone loss and consecutive
implementation of antiosteoporotic therapy, the risk of
osteoporotic fractures with the coinciding high morbid-
ity and mortality can be reduced, thereby achieving a
massive decrease in health care costs.
The most important risk factors identified by the
questionnaire are as follows:
Patient age represents a core variable for osteoporosis
risk [20] increasing age increases fracture risk [8,21].
Age related decreases in estrogen lead to disrupted
microarchitecture of trabecular bone [22]. Thus, age is
one of the most important risk factors for osteoporosis
and therefore was included in the DVO.
The loss of ≥ 4 cm body height is risk factor for
reduced BMD, and may result from vertebral sintering
due to osteoporotic change of trabecular structure. Joa-
kimsen et al. [23] showed that patients with a maximal
height of 168 cm suffered fracture of the lower extre-
mity 2.5 times more often.
Excessive alcohol consumption showed high signifi-
cance with reduced BMD in our study. Kanis et al. [24]
also demonstrated a correlation between high amounts
of alcohol consumption and reduced BMD. The cause
may be increased renal secretion of calcium. On the
other hand, low alcohol consumption (one glass of wine
per day) can positively influence bone mineral density
[25].
Similar osteoporotic findings exist for nicotine abu-
sers, due to a reduced enteral resorption of calcium
[26]. Comparing smokers and non-smokers Kanis et al.
[24] showed a significantly increased fracture rate in
smokers. In addition, Law et al. [27] found out that the
risk of bone loss caused by smoking is especially high in
postmenopausal women over the age of 60.
In the past, the high fracture rate under epileptic
patients was explained by the convulsive seizures; how-
ever, the anticonvulsive pharmaceuticals are now known
to reduce the enteral resorption of calcium, and thereby
causing the high prevalence of reduced bone density
found in this population [28-30].
Early menopause, before age 45, is also defined as a
risk factor for decreasing bone mass. The comparatively
short estrogen exposition time is thought to enhance
bone resorption [31]. Other authors propose nutrition
as the cause [32].
Table 2 Frequence of aberrations of bone specific
laboratory parameters in women, men and in total
men women total
Parathormone intakt 5 22 27
25 (OH) D3 7 35 42
ß-CTX 2 11 13
Pyridinoline (urine) 4 25 29
Procollagen Typ I N propeptide 1 14 15
Desoxypyridinoline (urine) 4 27 31
Creatinine (urine) 6 12 18
Estradiol 1 6 7
Homocysteine 7 44 51
Vitamin B12 2 4 6
Folate 3 22 25
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Figure 3 Diagram presenting the correlation between the
lowest T-values of DXA-measuring with increasing number of
pathologic laboratory parameters. The correlation of the seven
bone specific values and a reduced BMD is significant (p = 0.046,
Spearman’s rank correlation).
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Recent studies show that subclinical hyperthyroidism
leads to a decreased bone mineral density [33,34]. Postme-
nopausal women with hyperthyroidism are especially vul-
nerable to bone mass loss [35]. The mechanism of action
has been proposed by Katani et al. [36] and [37] Garnero
et al. to be trijodthyronine (T3) induction of differentiation
of osteoclasts. This leads to the creation of bone resorp-
tion products (e.g. pyridinoline, peptides of collagen) and
excretion of calcium in the urine. T3 also stimulates osteo-
blasts, but all in all the balance is negative.
Another highly significant factor in our study was the
immobilisation or inactivity of patients. Also Dargent-
Moline [38] showed that a reduced mobility, activity and
reduced musculature increases the risk of developing
osteoporosis. Due to the missing mechanical exposure of
the muscular-skeletal system, the bone tissue weakens
[39]. This explains why patients with multiple sclerosis
suffer a significantly reduced bone mineral density [40].
Our questionnaire represents a screening method; if
reduced BMD is suggested, a complete diagnosis with clin-
ical examination, laboratory tests, radiography and DXA
measurement remain the gold standard to achieve a pre-
cise diagnosis of the extent, cause, and indicated treatment
of pathological bone density.
As for the bone specific laboratory values, out of the
11 factors examined in this study, 7 showed a significant
correlation to a reduced BMD, and are discussed below.
Most of our patients showed a lack of 25-OH vitamin
D3, probably due to the reduced exposure to sunlight dur-
ing winter. The lack of D3 leads to PTH increase which
induces calcium decomposition in bone; possibly the
cause of the high PTH levels found in our patients.
Another cause of elevated PTH is primary or secondary
hyperthyroidism [41-43]. Both low D3 and high PTH are
important parameters in the diagnosis and treatment of
osteoporosis in the DVO guidelines [9].
One of the most significant markers for osteoblast activ-
ity is the PINP (procollagen type 1 N propeptide), which is
separated during synthesis of collagen. Increased values
indicate active bone formation, and is typical for malignant
tumors or osteoporosis [12,44,45].
Desoxypyridinoline is a decomposition product of col-
lagene and represents a specific marker for osteoclast
activity. Various studies proved its reliability [46-48].
Creatinine levels detect secondary osteoporosis due to
renal osteopathy. Homocysteine is mainly used for the
identification of an atherosclerotic risk profile. Increased
blood levels of homocysteine in conjunction with
decreased vitamin B12, leads to a reduced BMD and, as
reported by Leboff et al. [49] results in osteoporotic frac-
tures. Further studies presented same findings [50,51].
Stimulation of osteoclast activity is presumed to be the
mechanism by which a high level of homocysteine and a
low level of vitamin B12 reduces of BMD [52].
Conclusions
In conclusion, there is a high prevalence of undiagnosed
osteopenia and osteoporosis in patients suffering metaphy-
seal fractures. Both methods (medical questionnaire and
laboratory analysis) examined in our study present reliable
instruments for diagnostics of osteoporosis. Astonishingly,
the cost-effective and “simple” medical questionnaire
showed a high correlation with reduced BMD and there-
with presents next to the laboratory values a powerful
instrument for osteoporosis diagnostics.
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